NVAX · Novavax
AI read · Good for NVAX
The AI's read
This gives Novavax a path to partner payments and wider use of its vaccine technology. Sanofi's trial and manufacturing work are the clearest steps, and the company also cites a Pfizer collaboration with up to $500 million in possible milestones. Those payments are not secured: the trial has not started, and the manufacturing payment depends on completing a transfer. The $100 billion market figure covers a wide field, not Novavax sales. Still, partner interest and progress make the update favorable.